✦ LIBER ✦

Pharmacological evaluation of the cholinergic system in progressive supranuclear palsy

✍ Scribed by Dr. I. Litvan; R. Blesa; K. Clark; P. Nichelli; J. R. Atack; M. M. Mouradian; J. Grafman; T. N. Chase

Publisher: John Wiley and Sons
Year: 1994
Tongue: English
Weight: 649 KB
Volume: 36
Category: Article
ISSN: 0364-5134
DOI: 10.1002/ana.410360112

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Diagnostic accuracy of progressive supra

Diagnostic accuracy of progressive supranuclear palsy in the Society for Progressive Supranuclear Palsy Brain Bank

✍ Keith A. Josephs; Dennis W. Dickson 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB

## Abstract Diagnostic accuracy has been addressed previously for Parkinson's disease in a brain bank collection, but accuracy of progressive supranuclear palsy (PSP) has not been addressed in a similar setting. Clinical and genetic features of pathologically confirmed cases of PSP were compared wi

Genetic evidence for the involvement of

Genetic evidence for the involvement of τ in progressive supranuclear palsy

✍ Chris Conrad; Athena Andreadis; John Q. Trojanowski; Dennis W. Dickson; David Ka 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 538 KB

Mitochondrial impairment in the cerebell

Mitochondrial impairment in the cerebellum of the patients with progressive supranuclear palsy

✍ Larry C.H. Park; David S. Albers; Hui Xu; J. Gordon Lindsay; M. Flint Beal; Gary 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 134 KB

## Abstract Abnormalities in energy metabolism and oxidative stress accompany many neurodegenerative diseases, including progressive supranuclear palsy (PSP). Previously, we showed decreased activities of a mitochondrial enzyme complex, α‐ketoglutarate dehydrogenase complex (KGDHC), and marked incr

Efaroxan, an alpha-2 antagonist, in the

Efaroxan, an alpha-2 antagonist, in the treatment of progressive supranuclear palsy

✍ Prof. Olivier Rascol; Kasia Sieradzan; Hélène Peyro-Saint-Paul; Claire Thalamas; 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 413 KB

## Abstract We have tested, in a prospective randomized, double‐blind, placebo‐controlled, crossover, 12‐week study, the effects of 2 mg efaroxan, a potent alpha‐2 antagonist, given three times per day to 14 patients with progressive supranuclear palsy. Efaroxan did not induce any significant chang

Positron emission tomographic measuremen

Positron emission tomographic measurement of acetylcholinesterase activity reveals differential loss of ascending cholinergic systems in Parkinson's disease and progressive supranuclear palsy

✍ Hitoshi Shinotoh; Hiroki Namba; Mika Yamaguchi; Kiyoshi Fukushi; Shin-Ichiro Nag 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 522 KB

Increased tau burden in the cortices of

Increased tau burden in the cortices of progressive supranuclear palsy presenting with corticobasal syndrome

✍ Yoshio Tsuboi; Keith A. Josephs; Bradley F. Boeve; Irene Litvan; Richard J. Case 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB

## Abstract The objective of this study is to better define the pathological characteristics of pathologically proven progressive supranuclear palsy (PSP) presenting with the corticobasal syndrome (CBS). PSP is characterized by early falls, vertical supranuclear ophthalmoplegia, and axial rigidity,